Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Endocrine Society
2018-09-01
|
| Series: | Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-33-387.pdf |
| _version_ | 1818567326302208000 |
|---|---|
| author | Dug-Hyun Choi Chan-Hee Jung Ji-Oh Mok Chul-Hee Kim Sung-Koo Kang Bo-Yeon Kim |
| author_facet | Dug-Hyun Choi Chan-Hee Jung Ji-Oh Mok Chul-Hee Kim Sung-Koo Kang Bo-Yeon Kim |
| author_sort | Dug-Hyun Choi |
| collection | DOAJ |
| description | BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.MethodsAmong patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.ResultsA total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).ConclusionALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss. |
| first_indexed | 2024-12-14T06:21:57Z |
| format | Article |
| id | doaj.art-98fe42bfc11f4724a482f4e36545e2ef |
| institution | Directory Open Access Journal |
| issn | 2093-596X 2093-5978 |
| language | English |
| last_indexed | 2024-12-14T06:21:57Z |
| publishDate | 2018-09-01 |
| publisher | Korean Endocrine Society |
| record_format | Article |
| series | Endocrinology and Metabolism |
| spelling | doaj.art-98fe42bfc11f4724a482f4e36545e2ef2022-12-21T23:13:48ZengKorean Endocrine SocietyEndocrinology and Metabolism2093-596X2093-59782018-09-0133338739410.3803/EnM.2018.33.3.387Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver DiseaseDug-Hyun ChoiChan-Hee JungJi-Oh MokChul-Hee KimSung-Koo KangBo-Yeon KimBackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.MethodsAmong patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.ResultsA total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).ConclusionALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss.https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-33-387.pdfSodium-glucose cotransporter-2 inhibitorDiabetes mellitus, type 2Non-alcoholic fatty liver disease |
| spellingShingle | Dug-Hyun Choi Chan-Hee Jung Ji-Oh Mok Chul-Hee Kim Sung-Koo Kang Bo-Yeon Kim Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease Endocrinology and Metabolism Sodium-glucose cotransporter-2 inhibitor Diabetes mellitus, type 2 Non-alcoholic fatty liver disease |
| title | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| title_full | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| title_fullStr | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| title_full_unstemmed | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| title_short | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| title_sort | effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non alcoholic fatty liver disease |
| topic | Sodium-glucose cotransporter-2 inhibitor Diabetes mellitus, type 2 Non-alcoholic fatty liver disease |
| url | https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-33-387.pdf |
| work_keys_str_mv | AT dughyunchoi effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease AT chanheejung effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease AT jiohmok effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease AT chulheekim effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease AT sungkookang effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease AT boyeonkim effectofdapagliflozinonalanineaminotransferaseimprovementintype2diabetesmellituswithnonalcoholicfattyliverdisease |